TY - JOUR AU - Zhu, Viola W. AU - Ou, Sai-Hong Ignatius PY - 2018 TI - Pacific Rim redux: lorlatinib, the ultimate Jaeger? JF - Annals of Translational Medicine; Vol 6, Supplement 1 (November 29, 2018): Annals of Translational Medicine Y2 - 2018 KW - N2 - Lorlatinib is the most potent anaplastic lymphoma kinase (ALK) inhibitor to date based on pre-clinical models and also has excellent central nervous system penetration with an efflux/influx ratio of 1.5 (1). Emerging phase 1/2 data have demonstrated its efficacy in patients after disease progression on first- and second-generation ALK inhibitors (2). UR - https://atm.amegroups.org/article/view/21777